Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BPSD) Discussion Guide

This tool is designed to help providers understand, assess, and manage residents in LTC homes with behavioural and psychological symptoms of dementia (responsive behaviours), with a focus on antipsychotic medications. It was developed as part of Centre for Effective Practice’s Academic Detailing Service for LTC homes. This tool integrates best-practice evidence with clinical experience, and makes reference to relevant existing tools and services wherever possible.

Important principles include:

- Being resident-centred,
- Being mindful of benefits, risks and safety concerns,
- Using an interprofessional team approach and validated tools,
- Prescribing conservatively, and,
- Reassessing regularly for opportunities to deprescribe medications that are no longer needed.

As always, efforts must be made to individualize any treatment decisions for the resident, with consideration given to caregivers, family members, as well as LTC staff.

Identify BPSD Symptom Clusters\(^1, 2\)

<table>
<thead>
<tr>
<th>Psychosis</th>
<th>Aggression</th>
<th>Agitation</th>
<th>Depression</th>
<th>Mania</th>
<th>Apathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delusions</td>
<td>Defensive</td>
<td>Dressing/</td>
<td>Anxious</td>
<td>Euphoria</td>
<td>Amotivation</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>Resistance to care</td>
<td>undressing</td>
<td>Guilty</td>
<td>Irritable</td>
<td>Lacking interest</td>
</tr>
<tr>
<td>Misidentification</td>
<td>Verbal</td>
<td>Pacing</td>
<td>Hopeless</td>
<td>Irritable/screaming</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Suspicious</td>
<td>Physical</td>
<td>Repetitive actions</td>
<td>Irritable/screaming</td>
<td>Sad, tearful</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restless/anxious</td>
<td>Suicidal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Including symptoms that are not present but are inferred to be present. 
\(^2\) Including symptoms that are present but are not inferred to be present.
Overview of BPSD in LTC Management

Before beginning any sort of treatment (e.g. drug or non-drug therapy), it is important to evaluate the resident's symptoms. This section discusses:

- Tools for discussing and documenting BPSD
- How to use the P.I.E.C.E.S.™ tools to assess risks to the resident and others
- Clinical evaluations that should take place in order to identify any underlying physiological causes of BPSD

Section A: Evaluate BPSD in LTC

Section B: Initiate Non-Drug Therapy for BPSD in LTC

Non-drug therapy is an important part of managing BPSD, regardless of whether drug therapy is initiated. It is an ongoing process that involves the care team, family, and caregivers. This section discusses:

- Safety, environmental, and caregiver approach considerations that are core components of non-drug therapy
- Possible solutions to behavioural symptoms, including those identified within the Dementia Observation System (DOS)

Section C: Consider Drug Trial(s)

In some cases, when non-drug therapy approaches alone are not sufficient to manage BPSD, it may be necessary to initiate drug therapy to manage symptoms. This section discusses:

- Determining the best drug therapy to treat the resident's symptoms
- What symptoms are and are not likely to respond to antipsychotic therapy
- General principles for monitoring, documenting, and following-up on residents receiving medications

Section D: Additional Information on Antipsychotic Therapy

When BPSD are particularly distressing or disturbing, pose an imminent risk of harm to the patient or others, and are likely to respond to antipsychotics (see section C), it is sometimes beneficial to initiate antipsychotic therapy. This section expands on the information about antipsychotics introduced in Section C, and includes:

- The benefits and harms of antipsychotic therapy
- A table comparing the efficacy of different antipsychotics for treating BPSD, some common side effects, and the cost of treatment
- General guidelines for assessing antipsychotics for possible deprescribing
Section A: Evaluate BPSD in LTC

Remember: Engage the family/caregiver at every step. Discuss any history that may help the care team understand and manage the behaviour (e.g., preferences, activities, routine).

1. Assess & Document
   - Document behaviour or symptom clusters, including frequency, severity, triggers, and consequences
   - Designate specific members of the interprofessional care team who will be responsible for coordinating day-to-day assessment and management
   - Standardized clinical assessment tools, such as the Dementia Observation System (DOS) can be helpful for monitoring and documenting symptoms
   - Examples of standardized clinical assessment tools can be found on Page 7

2. Identify Risks
   - Use the P.I.E.C.E.S. mnemonic to assess risks to the resident and others:
     - Roaming: Is risk greater due to resident roaming?
     - Imminent: Is significant risk imminent?
     - Suicide: Does the resident display any suicidal tendencies?
     - Kin: Is the health or safety of residents/caregivers affected?
     - Self-neglect: Is resident’s self-neglect a risk to themselves or others?

3. Identify BPSD Causes
   - Obtain history from caregivers, family, and staff
   - Consider environmental factors and triggers, including possible role of team members
   - Consider using P.I.E.C.E.S. to identify causes (see box on right)

4. Clinical Evaluation
   - The differential diagnosis of the syndrome of behaviour change in dementia is broad. Careful examination of history, physical examination and appropriate investigations may help identify contributing factors. A full, rather than targeted, physical examination is indicated, within the bounds of patient cooperation.
   - History (include family/caregivers):
     - Recent changes to environment, routine, sleep pattern, family/social situation
     - Medication Review: Adherence, prescription and OTC medications, anticholinergic load, drugs that may increase agitation (e.g. cholinesterase inhibitors), medication induced hypotension or orthostatic hypotension, medication that may contribute to constipation and urinary retention, drugs and/or alcohol
   - Physical Examination:
     - Be mindful of sources of:
       - Pain (e.g. dental, skin, joint, feet)
       - Hydration (e.g. dehydration)
       - Sensory loss (hearing, vision)
       - CNS change (e.g. new stroke)
       - Infection (e.g. pneumonia, urosepsis)
       - Hypo-perfusion (e.g. new atrial fibrillation, heart failure)
       - Constipation and urinary retention
   - Laboratory and Imaging (as guided by physical exam/history):
     - Blood: Glucose, calcium, complete blood count (CBC), creatinine, electrolytes, TSH, others as appropriate
     - Urine: Any urinary symptoms? (Note: Caution not to send urine for culture if no urinary symptoms or sudden change in status as “asymptomatic bacteriuria” without lower urinary tract symptoms or symptoms of urosepsis/bacteremia are rarely the cause of increased behavioural symptoms)
     - Imaging: If appropriate (e.g. chest x-ray if suspected pneumonia based on physical exam; CT head if new concerning neurologic findings)

Use P.I.E.C.E.S.™ to Identify Causes

Use the P.I.E.C.E.S. 3-Question Template™ to ask:
1. What has changed?
2. What are the RISKS and possible causes?
3. What is the action?

Consider...

Physical think “the 5 Ds”
- Delirium
- Disease (cardiovascular, infectious, insomnia, metabolic, nocturia, renal, respiratory, sleep apnea, urinary retention, etc)
- Drugs (e.g. acetylcholinesterase inhibitors, anticholinergics, anticonvulsants, anti-Parkinson, benzodiazepines, digoxin, fluoroquinolones, lithium, opioids, systemic corticosteroid)
- See Reference List of Drugs with Anticholinergic Effects
- Discomfort (e.g. pain, constipation, fecal impaction, urinary retention, hunger, thirst)
- Disability (e.g. sensory loss)

Intellectual think “the 7 As”
- Amnesia (memory)
- Aphasia (speech)
- Apathy (initiative)
- Agnosia (recognition of people or things)
- Apraxia (purposeful movement)
- Anosognosia (insight/self-awareness)
- Altered Perception (sensory information)

Emotional think “the 4 Ds”
- Disorder Adjustment (e.g. related to losses)
- Disorders of Mood (e.g. depressive symptoms, anxiety)
- Delusional (e.g. suspiciousness, psychosis)
- Disorders of Personality

Capabilities
- Capability too low to meet demands of environment (catastrophic reactions) or not utilized enough (boredom)
- Maximize remaining strengths; avoid unnecessary disability

Environment
- Consider over-/under-stimulation, relocation, change in routine, noise, lighting, colours, social interactions with caregivers/others

Social
- Consider social network, life story, cultural/spiritual heritage
**Section B: Initiate Non-Drug Therapy for BPSD in LTC**

**Tips for Successful Non-Drug Therapy**

- As a general principle, individualize your approach as much as possible. Behavioural triggers and effective ways to treat them will vary from one resident to the next.
- Take advantage of any available system supports, such as Behavioural Supports Ontario (BSO) and Psychogeriatric Resource Consultants (PRCs). Even if non-drug therapy is successful at managing symptoms (i.e. drug therapy is unnecessary), monitor targeted behaviours for changes and follow-up regularly based on the needs of the resident/caregiver and severity of symptoms.

### Safety
- Ensure the resident’s safety and other residents’ safety by securing the environment
- Make sure you are safe (exit near, chair between you and resident)
- Remove potentially dangerous objects
- Move other individuals away
- Remove ongoing triggers

### Environmental Considerations

<table>
<thead>
<tr>
<th>Eliminate misleading stimuli</th>
<th>Reduce environmental stress</th>
<th>Adjust stimulation</th>
<th>Enhance function</th>
<th>Adapt the physical setting according to individual preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Clutter, TV, radio, noise, people, reflections in mirrors/dark windows, pictures/décor</td>
<td>- Caffeine, extra people, holiday decorations, public TV</td>
<td>- If over-stimulated, reduce noise, activity, confusion</td>
<td>- Increase lighting, to reduce misinterpretation</td>
<td>- Secure outdoor areas</td>
</tr>
<tr>
<td><strong>DOS Colours</strong></td>
<td></td>
<td><strong>DOS Colours</strong></td>
<td></td>
<td><strong>DOS Colours</strong></td>
</tr>
<tr>
<td>Orange</td>
<td>Brown</td>
<td>Pink</td>
<td>Red</td>
<td></td>
</tr>
<tr>
<td>Exit-seeking</td>
<td>Restless</td>
<td>Verbal aggression</td>
<td>Physical aggression</td>
<td></td>
</tr>
</tbody>
</table>

### Caregiver Approach Considerations

**Personal approach**
- Be calm and compassionate (use/avoid touch as indicated)
- Distract by engaging in individualized activities
- Focus on resident’s wishes, interests, concerns
- Approach slowly; look for signs of increase agitation
- Approach resident’s private space slowly and ask permission prior to entering

**Daily routines**
- Keep to the same routine to reduce uncertainty
- Use long-standing history and preferences to guide
- Individualize social and leisure activities to reduce boredom

**Communication style**
- Most communication is non-verbal, use positive non-verbal cues
- Make eye contact unless perceived as aggressive
- Use short simple words and phrases (residents with dementia have trouble processing multiple words)
- Speak clearly and use a positive tone
- Wait for answers (be patient)

### Behavioural Management

<table>
<thead>
<tr>
<th>Behaviour</th>
<th>Possible Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noisy (Yellow)</td>
<td>- Distract, engage</td>
</tr>
<tr>
<td></td>
<td>- Individualized music, nature sounds, presence therapy (tapes of family)</td>
</tr>
<tr>
<td>Restless (Orange)</td>
<td>- Distract, engage</td>
</tr>
<tr>
<td></td>
<td>- “Rest stations” in pacing path, adapt environment to reduce exit-seeking, physical exercise, outdoor activities</td>
</tr>
<tr>
<td>Exit-seeking (Brown)</td>
<td>- Distract, engage</td>
</tr>
<tr>
<td></td>
<td>- Adapt environment to reduce exit-seeking, physical exercise, outdoor activities</td>
</tr>
<tr>
<td></td>
<td>- Register the individual with MedicAlert and Alzheimer’s Society Safety Home program (contact information will be on bracelet or necklace)</td>
</tr>
<tr>
<td></td>
<td>- Hide exits with curtains, or paint a black circle on the floor (the individual will think it is a hole and will not exit)</td>
</tr>
<tr>
<td>Verbal aggression (Pink)</td>
<td>- Distract, engage</td>
</tr>
<tr>
<td></td>
<td>- Individualized music, nature sounds, presence therapy (tapes of family)</td>
</tr>
<tr>
<td>Physical aggression (Red)</td>
<td>- Distract, keep calm, remain warm and supportive</td>
</tr>
<tr>
<td></td>
<td>- If possible, give the person some space and try to approach later</td>
</tr>
<tr>
<td>Delusion/hallucination</td>
<td>- Understand this is their reality and do not confront the false belief</td>
</tr>
<tr>
<td></td>
<td>- Focus efforts on how the resident feels, not the content; offer distraction, avoid clutter, TV, radio</td>
</tr>
<tr>
<td>Agitated/irritated</td>
<td>- Calm, soothe, distract</td>
</tr>
<tr>
<td></td>
<td>- Individualized music, aromatherapy, pet therapy, physical exercise, outdoor activities</td>
</tr>
<tr>
<td>Resistant to care</td>
<td>- Identify source of threat (e.g. pain); change routines and approaches</td>
</tr>
<tr>
<td>Repetitive questions/ mannerisms</td>
<td>- Reassure, address underlying issue, distract</td>
</tr>
<tr>
<td></td>
<td>- Put the answer to the same repetitive question on a piece of paper or card and ask the resident to read the card instead</td>
</tr>
<tr>
<td>Hoarding</td>
<td>- Remove items gradually, re-organize and clear paths in the case of emergency; be compassionate</td>
</tr>
<tr>
<td>Inappropriate behaviour (e.g. disrobing, masturbation, verbally inappropriate)</td>
<td>- Distract, re-direct</td>
</tr>
<tr>
<td></td>
<td>- Keep an active and regular schedule to avoid boredom</td>
</tr>
<tr>
<td></td>
<td>- Try increasing the level of appropriate physical attention</td>
</tr>
<tr>
<td></td>
<td>- Provide personal space if possible and come back when the resident is calmer</td>
</tr>
<tr>
<td></td>
<td>- Allow the individual privacy for intimate/personal activities</td>
</tr>
</tbody>
</table>

*DOS = Dementia Observation System (Colours used in table are taken from the DOS system, though you may use different colours in your practice)*
Section C: Consider Drug Trial(s)

1 Ensure Drug Trial is Necessary
   - Treat underlying causes (e.g., pain, constipation, delirium)
   - Ensure that non-drug therapy options have been attempted and have been unsuccessful

   **Note:** In acute BPSD, if there is a safety risk to patient or others, there may not be time to try non-drug approaches before trying pharmacological management.

2 Select Appropriate Drug Trial
   - Select an appropriate drug based on symptoms (see chart at right)
   - Identify which behaviour(s) you wish to target (e.g., see symptom clusters on cover page and to right)

   - If you are considering initiating antipsychotic therapy, first ask:
     a. Are symptoms likely to respond to antipsychotics? (see below right)
     b. Is there imminent risk of harm to self and/or others?
     c. Are symptoms particularly disturbing, distressing or dangerous?
     d. Have you weighted the potential benefits and harms? (see page 6)
   - See page 6 for a detailed comparison of antipsychotics

   - Obtain and document informed consent (see Psychotropic Medication Consent Discussion Tool)
   - Start with a low dose, and gradually titrate as necessary/tolerated

3 Maintain and Review
   - Monitor change in targeted behaviour as well as side effects (see DOS Tool)
   - Assess over 1-3 weeks, documenting any benefits and harms realized. If lack of response and/or tolerability, adjust therapy. Increase dose (if not yet maximized) or taper/discontinue
   - Continue to reassess on an ongoing basis for effectiveness and tolerability
   - Consider dose reduction or discontinuation if the drug:
     a. Is not effective,
     b. Has intolerable side effects, or;
     c. Behaviours have been manageable and stable for 3-6+ months
   - If considering dose reduction/discontinuation for an antipsychotic, see "Reassessing Antipsychotics for Possible Deprescribing" on page 6

4 Follow-Up
   - Follow-up is important for any drug regimen
   - If antipsychotics used, reassess need at least every 3 months

5 Consider Referral to a Specialist if Drug Trial is Unsuccessful
   - If symptoms persist or worsen, consider referral to a specialist

6 Continue Non-Drug Approaches
   - Continue using non-drug approaches to prevent further BPSD symptoms

### Tips for Drug Trials and Deprescribing

- In all drug trials, unless clinically indicated, start at a low dose and increase or decrease slowly.
- For more tools and resources, visit effectivepractice.org/dementia.
- For more information about antipsychotic deprescribing, including a deprescribing algorithm, visit deprescribing.org.

### Selecting an Appropriate Drug Therapy for the Resident’s Symptom(s)

<table>
<thead>
<tr>
<th>Behaviour</th>
<th>Drug Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosis, Aggression, Agitation (severe)</td>
<td>Atypical antipsychotics (such as risperidone, aripiprazole, olanzapine, quetiapine) as discussed in detail on page 6</td>
</tr>
<tr>
<td>Agitation (severe), unlikely to respond to antipsychotics</td>
<td>SSRIs such as citalopram or trazodone (however, evidence is lacking for trazodone)</td>
</tr>
<tr>
<td>Agitation (severe) in Lewy Body Dementia or Parkinson’s</td>
<td>Possible cholinesterase inhibitors</td>
</tr>
<tr>
<td>Anxiety (short term/intermittent)</td>
<td>A short-acting benzodiazepine such as lorazepam prior to anxiety provoking events such as bathing</td>
</tr>
<tr>
<td>Anxiety (chronic)</td>
<td>Antidepressants (such as SSRIs, SNRIs)</td>
</tr>
<tr>
<td>Depression (severe)</td>
<td>Antidepressants such as SSRIs (e.g., citalopram, sertraline), SNRIs (e.g., venlafaxine, duloxetine), other antidepressants (bupropion, mirtazapine, moclobemide)</td>
</tr>
<tr>
<td>Mania</td>
<td>Addressing any possible drug causes is of primary importance</td>
</tr>
<tr>
<td>Apathy</td>
<td>Mood stabilizers are an option, but take caution regarding tolerability and drug interactions</td>
</tr>
</tbody>
</table>

### Symptom Likelihood to Respond to Antipsychotic Therapy

<table>
<thead>
<tr>
<th>Cluster</th>
<th>Likely</th>
<th>Unlikely</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosis</td>
<td>Delusions</td>
<td>Verbal</td>
</tr>
<tr>
<td></td>
<td>Hallucinations</td>
<td>Resistance to care</td>
</tr>
<tr>
<td></td>
<td>Misidentification</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suspicious</td>
<td></td>
</tr>
<tr>
<td>Aggression</td>
<td>Defensive</td>
<td>Restless/_anxious</td>
</tr>
<tr>
<td></td>
<td>Physical</td>
<td>Dressing/undressing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pacing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exit seeking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Repetitive actions</td>
</tr>
<tr>
<td>Agitation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>see below**</td>
<td>see below**</td>
</tr>
<tr>
<td>Mania</td>
<td>see below*</td>
<td>Euphoria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irritable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pressured speech</td>
</tr>
<tr>
<td>Apathy</td>
<td>Amotivation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lack of interest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Withdrawn</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Hiding or hoarding</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wandering without aggression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disinhibition (e.g., sexual)</td>
</tr>
</tbody>
</table>

* The role of antipsychotics in those with dementia and depression is beyond the scope of this evidence review.
** In cases where depression treatment may be indicated, consider psychiatric consultation to determine appropriate pharmacotherapy options.
**Section D: Additional Information on Antipsychotic Therapy**

**Potential Benefits and Harms of Antipsychotic Therapy**

Potential benefits tend to be over-appreciated, while harms are underappreciated. Nevertheless, when harmful behaviours are severe and distressing, an antipsychotic trial may be reasonable.

### Antipsychotics: Potential Benefits

**Limited benefit:** modest improvement seldom observed

- **Effect size:** 0.12-0.2
- **NNT variable:** ~5–14

(i.e. at best, compared to placebo, antipsychotic therapy results in targeted behaviour benefit in 1 out of 5 people treated)\(^16,11\)

### Antipsychotics: Potential Harms

**Side effects:** sedation, falls, postural hypotension, QT prolongation, confusion, EPS (rigidity, stiffness, akinesia), tardive dyskinesia, diabetes, weight gain\(^22,23\)

**Stroke:** increased risk

**Death:** possible increase

Health Canada Advisory noted a 1.6 fold increase in mortality (mostly related to heart failure, sudden death, pneumonia). Some data suggests that there will be 1 extra stroke or death for every ~100 people treated (NNH=100).\(^24,25,26\)

**KEY:** EPS: extrapyramidal symptoms (Parkinson’s-like); NNT: number needed to treat to see one extra benefit; NNH: number needed to treat to see one extra harm

### Comparison of Antipsychotics\(^20,21,30,31,32,33,34\)

Many effects are dose dependent and direct comparisons are limited. Thus, the following table is intended only as a general guide.

<table>
<thead>
<tr>
<th>Drug Generic (Brand)</th>
<th>Efficacy or evidence in BPSD therapy</th>
<th>BP(^{11})</th>
<th>Ach</th>
<th>Sedation</th>
<th>EPS</th>
<th>TD(^{11})</th>
<th>Diabetes</th>
<th>Weight Gain(^{27})</th>
<th>Usual Dose</th>
<th>$/Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone(^{*}) (Risperdal)(^{15,26,34})</td>
<td>• Indicated for severe dementia of the Alzheimer type (Health Canada) • Evidence for efficacy in agitation, aggression &amp; psychosis</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>0.125mg – 2.0mg/d</td>
<td>QHS (or divided BID)</td>
<td>$10-27</td>
</tr>
<tr>
<td>Olanzapine(^{*}) (Zyprexa)(^{15,26,34})</td>
<td>• Off-label use in BPSD • Evidence for efficacy in agitation &amp; aggression</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td>1.25mg – 7.5mg/d</td>
<td>$17-38</td>
<td></td>
</tr>
<tr>
<td>Aripiprazole(^{*}) (Abilify)(^{34})</td>
<td>• Off-label use in agitation or aggression(^{16}) • Evidence for efficacy in agitation &amp; aggression • Not eligible for dementia or BPSD in the elderly(^{15}) • Not for psychosis (same as placebo)</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>2.0mg – 12.5mg QHS</td>
<td>$112-260</td>
<td></td>
</tr>
<tr>
<td>Quetiapine (Seroquel)(^{15,26,34})</td>
<td>• Off-label use in BPSD • Lacks evidence for efficacy in BPSD agitation, aggression &amp; psychosis • Consider in Lewy Body dementia, Parkinson’s (low EPS) • Note: although used, not indicated, and lacking evidence for insomnia</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>12.5mg – 200mg/d (divided QHS-TID)</td>
<td>$10-59</td>
<td></td>
</tr>
<tr>
<td>Haloperidol (Haldol)</td>
<td>• Useful short term in acute BPSD or delirium</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>0.25mg – 2.0mg/d</td>
<td>$14-25</td>
<td></td>
</tr>
<tr>
<td>Loxapine (Loxapac, Xyloc)(^{1})</td>
<td>• Consider if other agents have failed and severe, persistent, dangerous behaviour continues • Severe, acute BPSD • Not to be used long-term due to adverse effects</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>–</td>
<td>5.0mg – 10mg BID</td>
<td>$18-27</td>
</tr>
</tbody>
</table>

\(^{*}\)Aripiprazole, olanzapine and risperidone were superior to placebo as treatment of behavioural symptoms as measured by total scores on BEHAVE-AD\(^{26}\), Brief Psychiatric Rating Scale (BPRS)\(^{31}\), and Neuropsychiatric Inventory (NPI)\(^{32}\)

**KEY:**

- **Ach:** anticholinergic
- **BP:** blood pressure
- **EPS:** extrapyramidal symptoms
- **IB:** pound
- **OB:** Ontario Drug Benefit
- **TD:** tardive dyskinesia
- **QHS:** bedtime

### Frequencies (%): Adverse Reactions of Antipsychotics at Therapeutic Doses

- **-** : Negligible or absent (<2%)
- **+++** : Frequent (>30%)
- **:***: Infrequent (>2%)
- **†**: Increase
- **+:** Moderate (>10%)

### Tips for Reassessing Antipsychotics for Possible Deprescribing

- Stopping or tapering antipsychotics may decrease “all cause mortality”\(^{27}\)
- Deprescribing may not be indicated where symptoms are due to psychosis, or where behaviour is especially dangerous or disruptive
- Evaluate reason for use and any recent changes in targeted behaviour
- Ensure suitable non-pharmacological measures for BPSD are optimized
- Due to the nature of responsive behaviours and the usual course of dementia, antipsychotics can often be successfully tapered and/or discontinued.\(^{15}\) As some may worsen, approach cautiously, and monitor behaviour\(^{15}\)
- Taper gradually, often by 25-50% every 2-4+ weeks and look for any resulting behaviour changes. Once on lowest dose, may discontinue in 2-4+ weeks
- Continue to reassess for emergence of responsive behaviours
Supporting Materials

These supporting materials are an inventory for long-term care providers to help identify useful clinical aids and resident/family material. This list includes direct links (where available) to tools or materials that have been directly referenced in the detailing guide and/or have been reviewed by CEP and identified as important material in supporting the uptake/adoption of the detailing guide. It includes a brief description of the tool, with full references available as indicated on page 8. The following is a comprehensive but not exhaustive list based on an environmental scan, appraisal by Clinical Leads, and focus groups with long-term care providers. CEP has also compiled a list of additional resources beyond those listed below available at effectivepractice.org/dementia

### Assessment and Practice Tools

- **Antecedent, Behaviour, Consequence (ABC) Chart Form**
  Chart form to help providers determine and document the events/stimuli that impact behaviour.
  
  **BEHAVE-AD**

- **Clinical rating scale to measure behavioural and psychological symptoms of dementia based upon information obtained from caregivers/informants.**
  
  **Brief Psychiatric Rating Scale**

- **Rating scale of 24 symptom constructs used to assess the positive, negative, and affective symptoms of individuals.**
  
  **Cohen-Mansfield Agitation Inventory (CMAI)**

- **Inventory questionnaire of grouped agitated behaviours to assess the frequency and severity of these behaviours in elderly persons.**
  
  **Confusion Assessment Method (CAM)**

- **Diagnostic algorithm/questionnaire for identification of delirium through formal cognitive testing.**
  
  **Cornell Scale for Depression in Dementia**

- **Scale for assessing signs and symptoms of major depression in people with cognitive impairment.**
  
  **Kingston Standardized Behavioural Assessment (KSBA)**

- **Behaviour analysis tool designed to indicate the number of behavioural symptoms associated with dementia affecting an individual patient.**
  
  **Neuropsychiatric Inventory – Nursing Home Version (NPI – NH)**

- **Tool to characterize the neuropsychiatric symptoms and psychopathology of patients with Alzheimer’s disease and other dementias to measure the impact of antidiementia and psychotropic drugs.**
  
  **Pain Assessment in Advanced Dementia Scale (PAINAD)**

- **Pain assessment tool for individuals with advanced dementia including behaviour observation scores.**
  
  **Dementia Observation System (DOS)**

- **Behaviour assessment tool which captures the frequency and duration of behaviours of concern over 24 hour periods.**
  
  **PIECES™ Framework**

- **Interdisciplinary approach to understanding and enhancing care for individuals with complex physical/cognitive/mental health need and behaviour changes.**
  
  **Psychotropic Medication Consent Discussion Tool**

- **Aid for initiating antipsychotic medications and key discussion items for informed consent from patients or substitute decision makers.**

### Reference and Support Information

- **Atypical Antipsychotic Drugs and Dementia – Advisories, Warnings and Recalls for Health Professionals**
  Advisory concerning atypical antipsychotic treatment of behavioural disorders in elderly patients, which is associated with an increased risk for all-cause mortality. June 2005
  
  **URL:** healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14307a-eng.php

- **Behavioural Supports Ontario (BSO)**
  Integrated network designed to provide services and supports to individuals with behaviours associated with complex mental health, dementia, and other neurological conditions living in long-term care.
  
  **URL:** brainexchange.ca/Public/Resource-Centre-Topics-A-to-Z/Behavioural-Supports-Ontario.aspx

- **Meaning and Solutions for Behaviours in Dementia Inventory**
  Dementia-related behaviors, including possible causess and solutions for management as a starting point for discussion with caregiver(s).
  
  **URL:** www.mountsinai.on.ca/care/psych/patient-programs/geriatric-psychiatry

- **Reference List of Drugs with Anticholinergic Effects**
  Reference list of drugs with low, moderate, and high anticholinergic effects, including side effects and preferred alternatives.
  
  **URL:** rxfiles.ca/rxfiles

- **Risperidone - Restriction of the Dementia Indication**
  Alert for the restriction of risperidone and related antipsychotic use to patients with severe dementia of the Alzheimer type unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. February, 2015
  
  **Note:** Although recent alert is specific for risperidone, other antipsychotics have similar concerns; however, unlike risperidone, others lack an official indication in BPSD.
  
  **URL:** healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43797a-eng.php

### Resident Materials

- **Antipsychotics and Dementia: Discussion Guide**
  Handout for families, caregivers, and co-residents discussing how antipsychotic medications are used to help people with dementia.
  
  **URL:** effectivepractice.org/dementia

- **Treating Disruptive Behaviour in People with Dementia (Patient Material)**
  Statements on how to treat disruptive behaviours without antipsychotic drug use.
  
  **URL:** choosingwisely.org
References


[31] University of Iowa College of Pharmacy. Antipsychotic medicines for people with dementia [Internet]. Iowa; Available from: https://www.healthcare.uow.edu/iiec/MPA/Adapt/View/ Antipsychotic_consumer.pdf.

[32] Reprinted with permission from Centre for Effective Practice. (April 2016). Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 2nd Edition). Use of antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 2nd Edition) for commercial purposes or any modifications of the tool are subject to charge and use must be negotiated with the Centre for Effective Practice (info@effectivepractice.org).

[33] For statistical and bibliographic purposes, please note the Centre for Effective Practice (info@effectivepractice.org) of any use or reprinting of the tool.

[34] Please use the below citation when referencing the tool:

Reprinted with Permission from Centre for Effective Practice. (April 2016). Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 2nd Edition) for commercial purposes or any modifications of the tool are subject to charge and use must be negotiated with the Centre for Effective Practice (info@effectivepractice.org).

This Tool was developed for Centre for Effective Practice (CEP) with input and review from our Academic Detailing Service Team, including our clinical leads Drs. Andrea Moser and Sid Feldman. In addition, target end-users and other relevant stakeholders provided input during the development process. This Tool was funded by the Province of Ontario as part of CEP’s Academic Detailing Service. For more information on the Academic Detailing Service, our Team and/or the development process please visit: effectivepractice.org/academidetailing.

This Tool was developed for licensed health care professionals in Long-Term Care as a guide only and does not constitute medical or other professional advice. Physicians, Nurse Practitioners, Pharmacists and other health care professionals are required to exercise their own clinical judgement in using this Tool. Neither the Centre for Effective Practice (“CEP”), nor any of the consultants, authors, agents, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, Long-Term Care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by third parties, including any information or advice contained therein.

Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 3rd Edition) is a product of the Centre for Effective Practice. Permission to use, copy and distribute this material for all non-commercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 3rd Edition) for commercial purposes or any modifications of the tool are subject to charge and use must be negotiated with the Centre for Effective Practice (info@effectivepractice.org).

Use of Antipsychotics in Behavioural and Psychological Symptoms of Dementia (BSPOD) Discussion Guide: Long-Term Care (LTC 2nd Edition) for commercial purposes or any modifications of the tool are subject to charge and use must be negotiated with the Centre for Effective Practice (info@effectivepractice.org).